. 2021 Apr 1;9(4):331. doi: 10.3390/vaccines9040331

Table 4.

Fetal HBsAg and anti-HBc status among mothers who were not treated by antivirals during pregnancy.

	Intention to Treat Analysis			Per Protocol Analysis
Variables, N (%)	Group A (n = 75) Engerix-B	Group B (n = 75) Sci-B-Vac	p Value	Group A (n = 75) Engerix-B	Group B (n = 67) Sci-B-Vac	p Value
HBsAg positivity in children according to Maternal viral loads
Undetectable viral load	1/11	0/18	0.3	1/11	0/17	0.3
	(9.1%)	0		(9.1%)	0
Detectable–1999 IU/mL	1/39	0/37	1	1/39	0/34	1
	(2.6%)	0		(2.6%)	0
2000–199,999 IU/mL	0/14	0/14	1	0/14	0/11	1
	0	0		0	0
200,000–7 log₁₀	1/4	0/3	1	1/4	0/2	1
	(25%)	0		(25%)	0
>7 log₁₀	2/7	1/3	0.9	2/7	1/3	0.6
	(28.6%)	(33.3%)		(28.6%)	(33.3%)
Anti-HBc positivity in children according to Maternal viral loads

Undetectable viral load	3/11	1/18	0.09	3/11	1/17	0.1
	(27.3%)	(5.6%)		(27.3%)	(5.9%)
Detectable–1999 IU/mL	11/39	12/37	0.6	11/39	12/34	0.5
	(28.2%)	(32.4%)		(28.2%)	(35.3%)
2000–199,999 IU/mL	5/14	5/14	1	5/14	4/11	0.9
	(35.7%)	(35.7%)		(35.7%)	(36.4%)
200,000–7 log₁₀	1/4	2/3	0.3	1/4	2/2	0.4
	(25%)	(66.7%)		(25%)	(100%)
>7 log₁₀	5/7	3/3	0.9	5/7	3/3	0.9
	(71.4%)	(100%)		(71.4%)	(100%)

Analysis excluding the six treated mothers with antivirals in group A and 10 mothers in group B, and excluding the five mothers with missing viral loads (1 in group A and 4 in group B) in the PPA and the ITT analysis.